Pyxus International Inc. (NYSE: PYX) is pleased to announce that its indirect Canadian subsidiary, Goldleaf Pharm Inc., has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) cultivation license from Health Canada. The license, awarded September 28, 2018, permits Goldleaf Pharm to begin cultivating medicinal cannabis at its Simcoe, Ontario facility.
“This is an important step, and an exciting time, for us at Goldleaf Pharm,” said Larry Huszczo, Goldleaf Pharm’s co-founder. “We have a state of the art 20,000 square foot indoor growing facility, and recently acquired 20-acres of adjacent property, giving us the ability to expand to more than 700,000 square feet of production space to cultivate cannabis. I am very proud of our team, which has worked diligently to meet Health Canada’s requirements.”
Goldleaf Pharm is a subsidiary of Pyxus’ indirect Canadian subsidiary, FIGR Inc. This latest milestone follows shortly after an announcement by FIGR that its Charlottetown subsidiary, Canada’s Island Garden Inc. (CIG), received approval from Health Canada for the sale of medicinal cannabis oils. CIG previously announced a supply agreement with the province of Prince Edward Island for 1,000 kilograms/kilogram equivalent of cannabis products.
With this development, FIGR’s two subsidiaries are now both licensed to produce medicinal cannabis in Canada. This also places FIGR’s subsidiaries in a position to produce cannabis for adult recreational use in Canada after October 17, 2018, when it is set to become legal in that country.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.